BB2121 Medicine 12 June 2019 Extended indication Multiple Myeloom Relapsed and Refractory Therapeutic value No judgement yet Total cost Registration phase Clinical trials Product Active substance BB2121 Domain Oncology and Hematology Reason of inclusion New medicine (specialité) Main indication Multiple Myeloma Extended indication Multiple Myeloom Relapsed and Refractory Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Celgene Portfolio holder Mechanism of action CAR-T therapy Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks CAR-T Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New medicine with Priority Medicines (PRIME) ATMP Unknown Submission date 2020 Expected Registration 2021 Orphan drug Unknown Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration 150 - 450 x 10^6 CAR+ T cells References KARMMA 3 NCT03651128 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR Additional remarks Zo'n 1200 patiënten komen jaarlijks in aanmerking voor een behandeling tegen MM. Gezien het hier gaat om "Relapsed and Refractory" patiënten zal slechts een deel van deze patiënten in aanmerking komen. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions No Indication extensions References AdisInsight Additional remarks Other information Additional remarks